CompletedNot Applicable

Serum Nesfatin-1 and Human Cartilage Glycoprotein-39 Levels in Knee Osteoarthritis

Turkey (Türkiye)30 participantsStarted 2022-06-01

Plain-language summary

In this study, our objective was to assess the correlation between serum human cartilage glycoprotein-39 (YKL-40) and nesfatin-1 values, the patient's clinical condition, ultrasonographic cartilage thickness measurements, and the response to PRP treatment in knee osteoarthritis (OA)

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Having patient consent, * Having stage 2-3 knee osteoarthritis according to the Kellgren-Lawrence scale, * Being diagnosed with knee osteoarthritis according to ACR (American college of Rheumatology), * Being over the age of 18 - under the age of 75, * Having NRS 4 and above Exclusion Criteria: * Those who have had knee surgery before, * Those who have had any local injections such as physical therapy, intra-articular steroid or hyaluronic acid injection in the knee area in the last 3 months, * Malignancies, * Those with local infection, wound, scar in the relevant area, * Infections, Hepatitis, Immunosuppression, * Inflammatory arthropathies, * Uncontrolled Hypertension, uncontrolled Diabetes Mellitus, decompensated heart failure, coronary artery disease, asthma * Recent trauma, * Epileptic patients, * Pregnant women, * Corticosteroid use, * Avascular necrosis * Anemia, bleeding coagulation disorder

What they're measuring

Change in Serum YKL-40 levels

Timeframe: before treatment (day 0), after exercise treatment (day 14), and after two doses of LP-PRP treatment combined with exercise treatment once a week (day 28).

Change in Serum nesfatin-1 levels

Timeframe: before treatment (day 0), after exercise treatment (day 14), and after two doses of LP-PRP treatment combined with exercise treatment once a week (day 28).

NRS pain score

Timeframe: before treatment (day 0), after exercise treatment (day 14), and after two doses of LP-PRP treatment combined with exercise treatment once a week (day 28).

WOMAC score

Timeframe: before treatment (day 0), after exercise treatment (day 14), and after two doses of LP-PRP treatment combined with exercise treatment once a week (day 28).

6 minutes walking test

Timeframe: before treatment (day 0), after exercise treatment (day 14), and after two doses of LP-PRP treatment combined with exercise treatment once a week (day 28).

Cartilage thickness measurement with USG

Timeframe: before treatment (day 0), after exercise treatment (day 14), and after two doses of LP-PRP treatment combined with exercise treatment once a week (day 28).

Trial details

NCT IDNCT06254976

SponsorKayseri City Hospital

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2023-06-01

View on ClinicalTrials.gov More Osteoarthritis of Knee trials

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Change in Serum YKL-40 levels

Timeframe: before treatment (day 0), after exercise treatment (day 14), and after two doses of LP-PRP treatment combined with exercise treatment once a week (day 28).

Change in Serum nesfatin-1 levels

Timeframe: before treatment (day 0), after exercise treatment (day 14), and after two doses of LP-PRP treatment combined with exercise treatment once a week (day 28).

NRS pain score

Timeframe: before treatment (day 0), after exercise treatment (day 14), and after two doses of LP-PRP treatment combined with exercise treatment once a week (day 28).

WOMAC score

Timeframe: before treatment (day 0), after exercise treatment (day 14), and after two doses of LP-PRP treatment combined with exercise treatment once a week (day 28).

6 minutes walking test

Timeframe: before treatment (day 0), after exercise treatment (day 14), and after two doses of LP-PRP treatment combined with exercise treatment once a week (day 28).

Cartilage thickness measurement with USG

Timeframe: before treatment (day 0), after exercise treatment (day 14), and after two doses of LP-PRP treatment combined with exercise treatment once a week (day 28).